Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 1:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 29,142 matching trials from the live ClinicalTrials.gov search.
Conditions
Diarrhea, Gastrointestinal Complications, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, cyclophosphamide
Biological · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Advanced Solid Malignancies
Interventions
REGN421(SAR153192)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Aurora, Colorado • Indianapolis, Indiana • Boston, Massachusetts + 5 more
Conditions
Healthy
Interventions
Enlicitide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Completed Early Phase 1 Interventional Accepts healthy volunteers

Follicle-Stimulating Hormone (FSH) and the Onset of Puberty

NCT00734279
Conditions
Delayed Puberty, Precocious Puberty
Interventions
Leuprolide Acetate - Early Puberty Leuprolide Visit, Ganirelix - Early Puberty Ganirelix Visit, Ganirelix - Delayed Puberty Ganirelix Visit, Leuprolide Acetate- Delayed Puberty Leuprolide Visit
Drug
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Psoriasis, Immunomodulation
Interventions
tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2623091 in Healthy Participants

NCT02300259
Conditions
Healthy Volunteers
Interventions
LY2623091, Itraconazole, Simvastatin, Tadalafil, Diltiazem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Exploration of Tolerability and Dose Responses for a Yeast-based Probiotic

NCT07867496
Conditions
Healthy Adult Participants, Gut Health
Interventions
9.9 x 10^7 Pichia kluyveri, 1 x 10^8 Pichia kluyveri, Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Fort Collins, Colorado
Conditions
Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Urinary Bladder, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
UGN-501
Biological
Lead sponsor
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Queen Creek, Arizona • Bakersfield, California • Murrieta, California + 12 more
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple-Dose Study of VGX-1027 in Healthy Subjects

NCT00760396
Conditions
Healthy
Interventions
VGX-1027
Drug
Lead sponsor
VGX Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Melanoma, Carcinoma, Renal Cell
Interventions
rh IL-15
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hypertrophic Cardiomyopathy
Interventions
TN-201
Genetic
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
10
States / cities
La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

NCT05476679
Conditions
Submental Fat
Interventions
RZL-012, RZL-012+Lidacaine injection prior treatment, RZL-012+Medrol, RZL-012+Celecoxib+Zyrtec, RZL-012+facial and neck wrap
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Manhattan, New York
Conditions
Colorectal Cancer
Interventions
SC-006, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Fayetteville, Arkansas • Los Angeles, California • Ann Arbor, Michigan + 6 more
Conditions
Acute Lymphoblastic Leukemia
Interventions
Everolimus, Prednisone, Vincristine, PEG-Asparaginase, Doxorubicin, Dexrazoxane
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Months to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 4 more
Conditions
Chronic Pain, Musculoskeletal Pain, Fibromyalgia, Virtual Reality
Interventions
Pain Rehabilitation Virtual Reality (PRVR), Standard Physiotherapy Rehabilitation (SPR)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Menlo Park, California • Palo Alto, California
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
42
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 37 more
Conditions
Obesity, Eating Disorders
Interventions
rimonabant (SR141716)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Mild Cognitive Impairment, Dementia
Interventions
bosutinib
Drug
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
45 Years to 89 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Acute Lymphoblastic Leukemia
Interventions
CMC-544 (Inotuzumab Ozogamycin), Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Glomerular Filtration Rate, Chronic Allograft Nephropathy
Interventions
sirolimus
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intravesical Gemcitabine with anti-CD40 antibody 2141-V11
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Metastatic Breast Cancer
Interventions
DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
44
States / cities
Tucson, Arizona • Fullerton, California • Los Angeles, California + 39 more
Conditions
Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma, Recurrent Skin Clear Cell Squamous Cell Carcinoma, Recurrent Skin Lymphoepithelial Carcinoma, Recurrent Skin Spindle Cell Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Resectable Eyelid Squamous Cell Carcinoma, Resectable Skin Acantholytic Squamous Cell Carcinoma, Resectable Skin Clear Cell Squamous Cell Carcinoma, Resectable Skin Lymphoepithelial Carcinoma, Resectable Skin Spindle Cell Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Skin Acantholytic Squamous Cell Carcinoma, Skin Clear Cell Squamous Cell Carcinoma, Skin Lymphoepithelial Carcinoma, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Surgical Procedure
Procedure · Biological · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
196
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more
Conditions
Renal Cell Carcinoma
Interventions
LBH589
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Fort Myers, Florida • Gainesville, Georgia • Baton Rouge, Louisiana + 7 more